News blog
Genentech, 23andMe to study genetic response to breast cancer drug
Personal genomics company 23andMe and biotechnology firm Genentech are recruiting breast cancer patients to study genetic predictors of how well they respond to the drug Avastin.
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells